Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Granules to acquire...

    Granules to acquire 12.5 pc stake in USpharma

    Written by savita thakur thakur Published On 2016-07-15T12:33:06+05:30  |  Updated On 15 July 2016 12:33 PM IST
    Granules to acquire 12.5 pc stake in USpharma

    Hyderabad : Granules India Ltd said its wholly-owned subsidiary Granules Pharmaceuticals Inc will acquire a 12.5 per cent stake in US-based USpharma for an undisclosed sum.


    According to a statement by Granules, the acquisition of the stake will enable it to participate in product selection and gain right of first refusal to market select products which are under development by USpharma.


    USpharma is a development-stage pharmaceutical company specialising in research, development and manufacture of high entry-barrier generic pharmaceuticals, including controlled release, controlled substance and patent-challenge products.


    USpharma, in collaboration with manufacturing partners, had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been licensed to Granules exclusively, it said.


    USpharma has formulation development and manufacturing facilities in Philadelphia and Pennsylvania in the US and a centre in Mumbai. It also has a CGMP (Current Good Manufacturing Practice) analytical laboratory in Kansas City, US.


    Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India said, "This agreement with USpharma complements our internal product development programme, and expands our product portfolio by leveraging external product development capabilities."


    "The successful development of limited competition products by USpharma provides further long-term growth for the company.


    "We are impressed with USpharma's product development capabilities with niche pipeline, and firmly believe that these products represent a substantial commercial opportunity," he added.

    Abbreviated New Drug ApplicationAcquisitionANDAcGMPCollaborationcurrent good manufacturing practicegeneric pharmaceuticalsGranulesKrishna Prasad ChigurupatiUSpharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok